On April 17, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Opioid Use Disorder (OUD), in collaboration with National Institute of Drug Abuse (NIDA). In addition to NIDA, FDA is also working closely with patient advocacy and community organizations to encourage participation from persons with OUD. This meeting aligns with FDA’s ongoing work aimed at reducing the impact of opioid abuse and addiction.
FDA is interested in learning patients’ perspectives on OUD, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for OUD, and challenges or barriers to accessing or using medical treatments for OUD.
The questions that will be asked of individuals with OUD at the meeting are listed below, organized by topic. For each topic, a brief initial panel of individuals with OUD and/or persons’ representing individuals with OUD will begin the dialogue. This will be followed by a facilitated discussion inviting comments from other participants in the audience. Webcast participants will also have an opportunity to provide input through webcast comments.